DK1660067T3 - Fremgangsmåder og materialer til behandling af lidelser forbundet med stofskiftesygdomme - Google Patents

Fremgangsmåder og materialer til behandling af lidelser forbundet med stofskiftesygdomme

Info

Publication number
DK1660067T3
DK1660067T3 DK04801850T DK04801850T DK1660067T3 DK 1660067 T3 DK1660067 T3 DK 1660067T3 DK 04801850 T DK04801850 T DK 04801850T DK 04801850 T DK04801850 T DK 04801850T DK 1660067 T3 DK1660067 T3 DK 1660067T3
Authority
DK
Denmark
Prior art keywords
methods
amino acid
disclosed
disorders
subject
Prior art date
Application number
DK04801850T
Other languages
English (en)
Other versions
DK1660067T4 (da
Inventor
Reuben Matalon
Original Assignee
Prekulab Ltd As Af 8 Marts 200
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34193087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1660067(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prekulab Ltd As Af 8 Marts 200 filed Critical Prekulab Ltd As Af 8 Marts 200
Application granted granted Critical
Publication of DK1660067T3 publication Critical patent/DK1660067T3/da
Publication of DK1660067T4 publication Critical patent/DK1660067T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
DK04801850.1T 2003-07-28 2004-04-19 Fremgangsmåder og materialer til behandling af lidelser forbundet med stofskiftesygdomme DK1660067T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49047303P 2003-07-28 2003-07-28
PCT/US2004/012120 WO2005016330A1 (en) 2003-07-28 2004-04-19 Methods and materials for treating conditions associated with metabolic disorders

Publications (2)

Publication Number Publication Date
DK1660067T3 true DK1660067T3 (da) 2008-11-10
DK1660067T4 DK1660067T4 (da) 2017-06-06

Family

ID=34193087

Family Applications (4)

Application Number Title Priority Date Filing Date
DK08001078.8T DK1920769T3 (da) 2003-07-28 2004-04-19 Fremgangsmåder og materialer til behandling af tilstande associeret med metaboliske sygdomme
DK04801850.1T DK1660067T4 (da) 2003-07-28 2004-04-19 Fremgangsmåder og materialer til behandling af lidelser forbundet med stofskiftesygdomme
DK200600147U DK200600147U4 (da) 2003-07-28 2006-05-22 LNAA-supplement og medikament til behandling af lidelser forbundet med stofskiftesygdomme
DK200600148U DK200600148U3 (da) 2003-07-28 2006-05-22 LNAA-supplement og medikament til behandling af lidelser forbundet med stofskiftesygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08001078.8T DK1920769T3 (da) 2003-07-28 2004-04-19 Fremgangsmåder og materialer til behandling af tilstande associeret med metaboliske sygdomme

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK200600147U DK200600147U4 (da) 2003-07-28 2006-05-22 LNAA-supplement og medikament til behandling af lidelser forbundet med stofskiftesygdomme
DK200600148U DK200600148U3 (da) 2003-07-28 2006-05-22 LNAA-supplement og medikament til behandling af lidelser forbundet med stofskiftesygdomme

Country Status (12)

Country Link
US (3) US20050027006A1 (da)
EP (2) EP1920769B1 (da)
CN (1) CN1856300B (da)
AT (1) ATE401069T2 (da)
DE (1) DE602004015115D1 (da)
DK (4) DK1920769T3 (da)
ES (2) ES2310763T3 (da)
HK (1) HK1098060A1 (da)
PL (2) PL1920769T3 (da)
PT (2) PT1660067E (da)
SI (1) SI1920769T1 (da)
WO (1) WO2005016330A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027006A1 (en) 2003-07-28 2005-02-03 Reuben Matalon Methods and materials for treating conditions associated with metabolic disorders
US20100317562A1 (en) * 2007-03-23 2010-12-16 Lynn Paolella Dietary Compositions
WO2016003263A1 (en) * 2014-07-01 2016-01-07 N.V. Nutricia Amino acid based diet with improved taste
US11701335B2 (en) * 2018-08-31 2023-07-18 Apr Applied Pharma Research S.A. Methods of normalizing amino acid metabolism
AU2020236023A1 (en) * 2019-03-14 2021-11-04 Hemoshear Therapeutics, Inc. Methods of treating organic acidemias

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832465A (en) * 1971-12-09 1974-08-27 H Ghadimi Injectable amino acid composition commensurate to the anabolic need of the body and method of using same
DE2654820C3 (de) † 1976-12-03 1986-07-31 Maizena Gmbh, 2000 Hamburg Aminosäuregemisch
US4209531A (en) * 1978-09-13 1980-06-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4252822A (en) * 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
DE3706402C1 (de) 1987-02-27 1988-07-07 Finckh Maschf Siebsegment fuer Filter zum Eindicken von Fasersuspensionen
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
DE3926440A1 (de) 1989-08-10 1991-02-14 Voith Gmbh J M Entwaesserungseinrichtung insbesondere banddruckfilter
US5411757A (en) * 1989-11-09 1995-05-02 Buist; Neil R. M. Palatable balanced amino acid-modified diet
DE4037447C2 (de) * 1990-11-24 1994-06-01 Milupa Ag Phenylalaninfreies Diätetikum für juvenile und adulte Personen mit Phenylketonurie sowie ein Verfahren zu seiner Herstellung
AU4842999A (en) 1998-06-30 2000-01-17 Arthrocare Corporation Systems and methods for electrosurgical ablation of viable body structures
US20050027006A1 (en) 2003-07-28 2005-02-03 Reuben Matalon Methods and materials for treating conditions associated with metabolic disorders

Also Published As

Publication number Publication date
DK1920769T3 (da) 2013-03-25
ES2310763T3 (es) 2009-01-16
US20110038932A1 (en) 2011-02-17
DK200600147U4 (da) 2006-10-13
DE602004015115D1 (de) 2008-08-28
WO2005016330A1 (en) 2005-02-24
EP1920769A1 (en) 2008-05-14
EP1920769B1 (en) 2013-01-16
DK1660067T4 (da) 2017-06-06
HK1098060A1 (en) 2007-07-13
US20120316215A1 (en) 2012-12-13
PL1660067T5 (pl) 2018-02-28
PT1920769E (pt) 2013-04-10
EP1660067A1 (en) 2006-05-31
DK200600148U3 (da) 2006-10-13
EP1660067A4 (en) 2006-08-30
US8252596B2 (en) 2012-08-28
PT1660067E (pt) 2008-10-27
US9820956B2 (en) 2017-11-21
CN1856300A (zh) 2006-11-01
US20050027006A1 (en) 2005-02-03
PL1920769T3 (pl) 2013-08-30
PL1660067T3 (pl) 2009-01-30
EP1660067B1 (en) 2008-07-16
CN1856300B (zh) 2012-04-11
ES2404049T3 (es) 2013-05-23
SI1920769T1 (sl) 2013-07-31
EP1660067B2 (en) 2017-03-15
DK200600147U1 (da) 2006-09-22
ATE401069T2 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
Brosnan et al. Histidine metabolism and function
Wu Important roles of dietary taurine, creatine, carnosine, anserine and 4-hydroxyproline in human nutrition and health
WO2002043507A3 (en) Nutrient supplements and methods for treating autism and for preventing the onset of autism
MY147489A (en) Methods for the treatment of muscle loss
WO2006009437A3 (en) Use of aspartate for regulating glucose levels in blood
IL208184A0 (en) Glp-1, and methods for treating diabetes
WO2007113648A3 (en) Ctla4 antibody combination therapy
HK1098060A1 (en) A large neutral amino acid supplement for treating conditions associated with metabolic disorders
US20040033252A1 (en) Agents for recoverying from or preventing fatigue in the central nerve system and foods for recovering from or preventing fatigue
TW200719908A (en) Dermatologic use of milk proteins
WO2009090656A3 (en) Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
BRPI0720230A2 (pt) Uso de uma formulação nutricional oralmente administrável, formulação nutricional, método para tratar um distúrbio desenvolvimental penetrante, e, composição
ID27818A (id) Metode untuk menyediakan glutamin
WO2003061681A3 (en) Proteins involved in the regulation of energy homeostasis and organelle metabolism
WO2006134135A3 (en) Nutritional method for elderly people
Ingenbleek et al. The essentiality of sulfur is closely related to nitrogen metabolism: a clue to hyperhomocysteinaemia
KR950010884A (ko) 사람 및 동물에서 염증성 반응을 일으키는 공격 또는 패혈증 치료용의 아미노산계 조성물
Holecek Adverse effects of chronic intake of glutamine-supplemented diet on amino acid concentrations and protein metabolism in rat: effect of short-term starvation
Patel et al. Protein supplementation: the double-edged sword
Crittenden et al. Functional dairy protein supplements for elite athletes
Okame et al. Comparison of amino acid profiles between rats subjected to forced running and voluntary running exercises
DK1581239T3 (da) Tidlig anvendelse af et ekstrakt af røde vinblade
CY1113947T1 (el) Μεθοδοι και υλικα για θεραπεια καταστασεων που σχετιζονται με μεταβολικες διαταραχες
ZA200608865B (en) Biologically active peptide VAPEEHPTLLTEAPLNPK derivatives
Kamble et al. A Review on Amino Acids. Research & Reviews: A Journal of Drug Design & Discovery. 2021; 8 (3): 19–27p